Crossmark

Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes

Published Online: 2024-10-24

Published Print: 2025-04

Authors

Mallone, Roberto https://orcid.org/0000-0002-9846-8861
License Information

Text and Data Mining valid from 2024-10-24

Version of Record valid from 2024-10-24
More Information

Article History

Received: 13 July 2024

Accepted: 8 August 2024

First Online: 24 October 2024

Funding

: Work in the author’s laboratory is supported by The Leona M. & Harry B. Helmsley Charitable Trust (grants 1901-03689 and 2412-07951), EU H2023 (grant 101137457 [ENT1DEP]) and the Innovative Medicines Initiative 2 Joint Undertaking (grants 115797 [INNODIA] and 945268 [INNODIA HARVEST]), which receives support from the EU Horizon 2020 programme, the European Federation of Pharmaceutical Industries and Associations, JDRF and The Leona M. & Harry B. Helmsley Charitable Trust.

: RM serves or has served on advisory panels for Immunocore, King’s College London, Amarna Therapeutics; financial compensation for these activities has been received by INNODIA iVZW or the APHP Foundation. RM serves on the advisory panel of and owns stocks in Endotope Biosciences. RM has received honoraria as a speaker for Novo Nordisk and Eli Lilly. RM serves on speakers’ bureaus for Sanofi; financial compensation for these activities is received by the APHP Foundation. Inserm has received research support for RM from Provention Bio.

: RM was the sole contributor to this paper.

Document is current